Previous 10 | Next 10 |
Reports record revenue, generates positive free cash flow, expects 2024 revenue of $2.810-2.850 billion Fourth quarter and 2023 highlights Total fourth quarter revenue of $647 million, an increase of 17%, or 18% on a core revenue basis, with Screening revenue of $487 million and Pre...
Vimeo Inc. (VMEO) is expected to report $-0.01 for Q4 2023 Heineken N.V ADR (HEINY) is expected to report for Q4 2023 American States Water Company (AWR) is expected to report $0.53 for Q4 2023 NextPlay Technologies Inc. (NXTP) is expected to report for Q3 2024 Inseego Corp. (INSG...
2024-02-20 17:20:07 ET More on Exact Sciences Exact Sciences: Growing Revenue With An Innovative Approach To Oncology Exact Sciences preliminary Q4 revenue beats Street estimates; CFO to step down It's JPM time! Which medtechs are expected to issue updates this week?...
2024-02-20 13:11:04 ET More on Markets Biggest stock movers today: Walmart, Discover Financial Services, Barclays, and more Capital One/Discover merger comes despite slow deal-making environment Investors retract capital from the fund market for the third week in fou...
2024-02-18 08:20:00 ET Despite a holiday-shortened week, investors have their plates full with a diverse range of earnings reports across various sectors. Tech leaders NVIDIA ( NASDAQ: NVDA ) and Palo Alto Networks ( NASDAQ: PANW ) will be in focus, alongside retail gian...
2024-02-14 15:41:42 ET More on CRISPR, Intellia Therapeutics, etc. Intellia's Bet On In-Vivo Breakthroughs: A Perspective On CRISPR's Next Frontier Crispr Therapeutics: Investors Bet Against Casgevy Uptake Biotech And Pharma Diversification Pays Off Vertex, C...
2024-02-07 09:00:00 ET Some investors are famous enough that their every move is scrutinized. That's the case with Cathie Wood, CEO of Ark Invest, an investment management firm. Wood's firm recently sold thousands of shares of cancer diagnostics specialist Exact Sciences (NASDAQ: EXAS...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2023 financial results after the close of the U.S. financial markets on February 21, 2024. Following the release, company manageme...
2024-01-28 09:25:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips I’m bullish on the long-term trajectory of personalized medicine stocks. These companies specialize in tailoring a holistic approach to healthcare, with medical treatments tailored to th...
2024-01-25 11:45:37 ET Summary Exact Sciences reported a 17% increase in total revenue in Q4 2023, driven by the Screening and Precision Oncology segments. The company's innovative products, such as Cologuard and Oncotype DX, are reshaping cancer screening and treatment paradigms....
News, Short Squeeze, Breakout and More Instantly...
Exact Sciences Corporation Company Name:
EXAS Stock Symbol:
NASDAQ Market:
Exact Sciences Corporation Website:
2024-07-11 08:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-08 08:30:00 ET To say that Exact Sciences (NASDAQ: EXAS) hasn't performed well on the stock market this year would be an understatement. Shares of the cancer-focused biotech are down by 41%. However, the healthcare company still has some fans on Wall Street. Cathie Wood ...
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its second quarter 2024 financial results after the close of the U.S. financial markets on July 31, 2024. Following the release, company management w...